Literature DB >> 3005572

Crystal structure of the dihydropyridine Ca2+ antagonist felodipine. Dihydropyridine binding prerequisites assessed from crystallographic data.

R Fossheim.   

Abstract

The molecular structure of the dihydropyridine Ca2+ antagonist felodipine (ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(2,3-dichlorophenyl)-3,5-pyridinedicarboxy late) has been determined by X-ray crystallographic methods. The dihydropyridine ring in this potent smooth muscle relaxant is among the flattest found in such structures. This is in qualitative agreement with previous investigations of dihydropyridine Ca2+ antagonists; deviations from planarity in the dihydropyridine ring are generally smallest in the most active compounds. Hydrogen-bonding patterns observed in the crystal lattices of several dihydropyridine Ca2+ antagonists are compared. Antiperiplanar carbonyl groups are partly shielded from forming hydrogen bonds in compounds with relatively bulky ortho phenyl substituents. Conformational prerequisites for a favorable hydrogen-bonding geometry toward a receptor site may thus involve synperiplanar carbonyl groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005572     DOI: 10.1021/jm00152a023

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Synthesis and calcium channel antagonist activity of 3-arylmethyl 5-isopropyl 1,4-dihydro-2,6-dimethyl-4-(pyridyl)-3,5-pyridinedicarboxylates.

Authors:  M R Akula; W C Matowe; M W Wolowyk; E E Knaus
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

2.  Application of electron conformational-genetic algorithm approach to 1,4-dihydropyridines as calcium channel antagonists: pharmacophore identification and bioactivity prediction.

Authors:  Nazmiye Geçen; Emin Sarıpınar; Ersin Yanmaz; Kader Sahin
Journal:  J Mol Model       Date:  2011-03-31       Impact factor: 1.810

3.  Influence of particle size on the ultraviolet spectrum of particulate-containing solutions: implications for in-situ concentration monitoring using UV/Vis fiber-optic probes.

Authors:  Bernard Van Eerdenbrugh; David E Alonzo; Lynne S Taylor
Journal:  Pharm Res       Date:  2011-03-04       Impact factor: 4.200

4.  A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers.

Authors:  Xiaolin Charlie Tang; Michael J Pikal; Lynne S Taylor
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

5.  The effect of temperature on hydrogen bonding in crystalline and amorphous phases in dihydropyrine calcium channel blockers.

Authors:  Xiaolin Charlie Tang; Michael J Pikal; Lynne S Taylor
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

Review 6.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

7.  Receptor model for the molecular basis of tissue selectivity of 1, 4-dihydropyridine calcium channel drugs.

Authors:  D A Langs; P D Strong; D J Triggle
Journal:  J Comput Aided Mol Des       Date:  1990-09       Impact factor: 3.686

8.  The effect of bromine scanning around the phenyl group of 4-phenylquinolone derivatives.

Authors:  Scott A Steiger; Anthony J Monacelli; Chun Li; Janet L Hunting; Nicholas R Natale
Journal:  Acta Crystallogr C Struct Chem       Date:  2014-07-31       Impact factor: 1.172

9.  Novel halogenated dihydropyridine derivatives with high vascular selectivity.

Authors:  U Fricke; W Klaus; B Stein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-10       Impact factor: 3.000

10.  Exploring molecular reorientations in amorphous and recrystallized felodipine at the microscopic level.

Authors:  A Pajzderska; J Jenczyk; J P Embs; J Wąsicki
Journal:  RSC Adv       Date:  2020-10-08       Impact factor: 4.036

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.